WIN Consortium
- Company typePrivate
- Founded2010
- HeadquartersVillejuif, France
- Headcount1–10
- GTM typeB2B
- OfferingServices
WIN Consortium firmographics
Firmographics- Name
- WIN Consortium
- Legal name
- Worldwide Innovative Network (WIN) Association
- Website
- https://winconsortium.org
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
WIN Consortium industry classification
Industry- Product category
- Precision Oncology Research
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Voluntary Health Organizations (813212), Professional Organizations (813920)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials) (HLAAANAI)
Keywords
Where WIN Consortium is headquartered
LocationHeadquarters
- HQ city
- Villejuif
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
WIN Consortium business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Institutional Membership Fees: WIN Consortium operates as a non-profit, non-governmental organization funded through membership contributions from 38 institutional members including academic cancer centers, life science companies, biotech organizations, and technology companies. Membership fees support consortium operations and global clinical trial activities.
- Research Grants and Philanthropy: Funded by organizations such as ARC Fondation for cancer research (France), pharmaceutical partners who donate drugs for trials (e.g., Pfizer Inc.), and other cancer research foundations.
Go-to-market motion1 record
Distribution channels3 records
Marketing channels5 records
WIN Consortium product offering
Product offeringCore offering
WIN Consortium is a global non-profit research consortium that designs and conducts collaborative clinical trials and research projects in precision oncology. Its core offerings include the WINTHER personalized medicine trial (RNA + DNA profiling), the SPRING lung cancer tri-therapy trial, the Digital Display Precision Predictor (DDPP) biomarker model, and the annual WIN Symposia. The consortium serves academic cancer centers, pharmaceutical and biotech companies, and technology firms through membership-based participation in global research.
Product overview
WIN Consortium is a non-profit, non-governmental research organization focused on accelerating precision oncology through global clinical trials and collaborative research. The consortium does not offer commercial products or services; instead, it conducts collaborative studies including WINTHER (genomic/transcriptomic profiling trial), SPRING (lung cancer tri-therapy trial), and DDPP (Digital Display Precision Predictor biomarker model). WIN also organizes annual symposia for knowledge exchange among its global member institutions.
Differentiator
Problem solved
Functional benefit
Products and services
- WIN Consortium Membership
- Digital Display Precision Predictor (DDPP)
- SPRING Clinical Trial
- WINTHER Clinical Trial WIN's first global personalized medicine clinical trial, demonstrating that RNA profiling together with DNA testing matches more patients with advanced cancer to personalized therapies than DNA profiling alone. Enrolled 101 patients with various metastatic cancers, exploring transcriptomic and genomic profiling data with both tumor and normal organ-matched tissue. Results published in Nature Medicine.
- WIN Symposia Series Annual scientific symposia bringing together hundreds of global leaders in precision oncology to exchange ideas, share research findings, and engage new member institutions. ASCO-endorsed for 14 consecutive years. WIN 2024 (Abu Dhabi) had 450+ attendees from approximately 30 countries. WIN 2025 is featured as the Oncology Track of the APM Annual Conference in Philadelphia.
Quantifiable outcome
- RNA profiling with DNA testing matches more patients to personalized therapies than DNA profiling alone (WINTHER trial, Nature Medicine)
- +2 more outcomes
Companies that use WIN Consortium
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles3 records
WIN Consortium technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
WIN Consortium partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered core and major.
- SWOG Cancer Research NetworkcoreSWOG Cancer Research Network, one of the five network groups in NCI's National Clinical Trials Network (NCTN), has joined WIN Consortium. This alliance combines two organizations with deeply aligned missions to accelerate progress against cancer. SWOG will collaborate with WIN and its member institutions to advance precision medicine and biomarker-driven research, aiming to reduce the cost of cancer care while improving clinical effectiveness globally.
- Advancing Precision Medicine (APM) ConferencemajorWIN Symposium 2025 featured as the Oncology Track of the APM Annual Conference held at Pennsylvania Convention Center, Philadelphia. This partnership positions WIN as a major track within a larger precision medicine conference, extending reach to broader audience including multi-omics and disease-specific tracks.
- TempuscoreWIN Consortium is supporting the activation of the Tempus GEMINI-NSCLC study at member institutions in the USA, Canada, Europe, and the Middle East. Tempus deploys its comprehensive molecular profiling platform—including solid tumor (xT/xR) and liquid biopsy (xF)—to analyze tumor biology longitudinally in the study. The study focuses on understanding disease progression and treatment response with emphasis on identifying novel biomarkers and ctDNA for MRD monitoring.
- Journal of Immunotherapy and Precision Oncology (JIPO)majorJIPO and WIN renewed their cooperation to cover the WIN 2024 symposium. JIPO publishes the symposium abstracts. Dr. Vladimir Lazar, WIN Chief Scientific and Operating Officer, was appointed to the JIPO Editorial Board. This partnership provides peer-reviewed publication outlet for WIN research and enhances visibility of consortium activities.
- Burjeel HoldingsmajorWIN Consortium partnered with Burjeel Holdings for the WIN 2024 Symposium held at Rosewood Hotel in Abu Dhabi, UAE. Theme was 'Precision and Molecular Oncology: Caring for Patients and Future Generations.' Burjeel's Group Chief Research Officer, Khaled Musallam, served as Symposium Chairperson. The partnership brought together 450+ clinicians, researchers, and industry professionals from 30 countries.
- Pfizer Inc.corePfizer Inc. donated drugs for the WIN SPRING clinical trial. The pharmaceutical partnership enabled the landmark tri-therapy clinical trial exploring combination targeted drug strategies in first-line advanced/metastatic non-small cell lung cancer.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
WIN Consortium competitors and assessment
Company assessmentEmerging players
- Stand Up To Cancer: Charitable program funding collaborative translational cancer research including precision oncology teams. Comparable mission of accelerating breakthrough cancer therapies through cross-institution collaboration, but functions primarily as a funder rather than a trial operator.
Regional players
- Cancer Research UK: U.K.-headquartered cancer research charity funding translational and clinical research. Adjacent in mission of accelerating precision oncology research and trial support, but U.K.-centric rather than globally distributed.
Direct peers
- NRG Oncology: NCI NCTN group running biomarker-driven oncology clinical trials across U.S. and international sites. Comparable as a multi-institutional oncology research network running Phase I-III trials with academic and pharma partners.
- European Organisation for Research and Treatment of Cancer (EORTC): Europe-headquartered cooperative group conducting multi-center oncology clinical trials with global site participation. Directly comparable as a non-profit, multi-country precision oncology trial network with membership model similar to WIN.
- SWOG Cancer Research Network: One of NCI's five NCTN groups running multi-center oncology clinical trials. Directly comparable as a collaborative clinical trials network, and now an actual WIN Consortium partner following the December 2025 alliance.
- Alliance for Clinical Trials in Oncology: NCI NCTN group running oncology trials across U.S. academic centers. Comparable multi-institutional oncology trial network structure with shared membership and study design model.
- ECOG-ACRIN Cancer Research Group: NCI NCTN group conducting precision medicine and biomarker-driven cancer trials. Comparable as a similarly structured collaborative oncology research consortium with multi-institutional trial design and execution.
Broad incumbents
- American Association for Cancer Research (AACR): Large professional society advancing cancer research including precision oncology, publishing flagship journals and running scientific conferences. Overlapping scientific and convening role with WIN Symposia, but broader non-trial scope.
- American Society of Clinical Oncology (ASCO): Leading oncology professional society that has endorsed WIN Symposia for 14 consecutive years. Comparable as a global oncology convening and standards-setting body, though it is a professional society rather than a trial-conducting consortium.
Others
- Foundation for the National Institutes of Health (FNIH): U.S. nonprofit that manages public-private biomedical research partnerships for NIH including oncology initiatives. Comparable as an enabling, multi-stakeholder precision research convener, but does not itself run patient trials.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
WIN Consortium social profiles
Digital presenceWIN Consortium compliance and trust
Trust signalCompliance1 record
WIN Consortium financial estimates
Financial estimateRevenue estimate
Valuation estimate
WIN Consortium leadership team
Management profileNumber of profiles
Profiles12 records
WIN Consortium funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
WIN Consortium M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about WIN Consortium
What does WIN Consortium do?
WIN Consortium is a global non-profit research consortium that designs and conducts collaborative clinical trials and research projects in precision oncology. Its core offerings include the WINTHER personalized medicine trial (RNA + DNA profiling), the SPRING lung cancer tri-therapy trial, the Digital Display Precision Predictor (DDPP) biomarker model, and the annual WIN Symposia. The consortium serves academic cancer centers, pharmaceutical and biotech companies, and technology firms through membership-based participation in global research.
Is WIN Consortium a public or private company?
WIN Consortium is a private company. It is classified as nonprofit foundation owned and is currently operating.
When was WIN Consortium founded?
WIN Consortium was founded in 2010. It employs 1 to 10 people.
Where is WIN Consortium based?
WIN Consortium is headquartered in Villejuif, France, in the Europe region.
How does WIN Consortium make money?
Two revenue lines are on record. Institutional Membership Fees are the primary driver. The others are research Grants and Philanthropy.
Who are WIN Consortium's main competitors?
Stand Up To Cancer is listed as an emerging player. Cancer Research UK is listed as a regional player. Direct peers are NRG Oncology, European Organisation for Research and Treatment of Cancer (EORTC), SWOG Cancer Research Network, Alliance for Clinical Trials in Oncology and ECOG-ACRIN Cancer Research Group. Broad incumbents are American Association for Cancer Research (AACR) and American Society of Clinical Oncology (ASCO). Foundation for the National Institutes of Health (FNIH) is listed as an others.
Does WIN Consortium have an API?
No public API is recorded for WIN Consortium.
What industry is WIN Consortium in?
WIN Consortium's product category is Precision Oncology Research. Its primary akta.pro industry code is HLAAANAI, Precision Clinical Trials Enablement (patient matching, site matching, adaptive trials). Its NAICS code is 541714 and its SIC code is 8731.